echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novartis resubmitted its cholesterol-lowering drug inclisiran's application for marketing in the U.S. by transferring production

    Novartis resubmitted its cholesterol-lowering drug inclisiran's application for marketing in the U.S. by transferring production

    • Last Update: 2021-08-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compileriver

    In December last year, the FDA rejected Novartis’ siRNA cholesterol-lowering drug Leqvio (inclisiran) due to the inability to complete the production site inspection on time


    Leqvio is an interfering RNA (siRNA) drug targeting PCSK9.


    Leqvio is a core product that Novartis acquired from Medicines Pharmaceuticals at a cost of US$9.


    In addition to rejections related to production verification, the new crown pandemic has also affected an important trial of the drug


    Currently, Leqvio's data can only show that it can reduce harmful cholesterol levels


    Novartis launched Leqvio in Germany and Austria in February this year for patients with extremely high cardiovascular risk


    Reference source: Novartis revives inclisiran US filing by sidestepping FDA's manufacturing inspection concerns

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.